Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA

November 28, 2023 11:00 AM AEDT | By Cision

Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA — Image source: Kalkine Media

Recent News

Kasada’s Q1 2025 Threat Intel Report Uncovers ALTSRUS “Reverse Robin H...

Asana Launches Smart Workflow Gallery, a Blueprint for Effective Human...

Planet Signs 7-Figure Contract Expansion with the German Government, E...

SugarCRM Announces sales-i Now Fully Integrated with Sugar Sell

SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority of Brazil, ANVISA.

Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and Chang-Jae Lee, proudly announced that their Osong factory passed the Brazilian Good Manufacturing Practice (GMP) inspection with a flawless "Zero" Observation in terms of compliance. This success in the rigorous GMP inspection underscores the Osong plant's commitment to the highest quality standards and the excellence of its smart manufacturing practices.

This Successful Inspection paves the way for Daewoong Pharmaceutical to further its entry into the Brazilian pharmaceutical market.

Brazil's GMP review is known to be challenging, involving stringent requirements. ANVISA actively conducts on-site inspections overseas, meticulously examines not only pharmaceutical quality management on-site but also data integrity, manufacturing facilities, and compliance with GMP in production processes. Within the industry, passing Brazil's GMP without any issues is publicly recognized as a difficult task, and achieving a flawless inspection is considered a remarkable accomplishment.

Daewoong Pharmaceutical emphasized the crucial role of the Level 4 smart factory system in the Osong Plant. Level 4 facilitates proactive measures and optimal decision-making, allowing for advanced process operation simulations where data integrity is demonstrable.

Daewoong Pharmaceutical, leveraging its smart process, plans to actively pursue GMP certifications in additional countries, including developed nations. This strategic move aims to establish a smooth global expansion of their innovative drugs.

Forward-Looking Statements

This press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management. Factors that could cause or contribute to such differences include, but are not limited to: (1) Regulatory and governmental approvals: The approval process for pharmaceutical products is subject to extensive regulations and may involve uncertainties and delays. Any failure to obtain necessary approvals or the occurrence of delays in the approval process could adversely affect Daewoong Pharmaceutical's business and results of operations; and (2) Clinical trials: The success of Daewoong Pharmaceutical's products depends on the results of clinical trials. The results of early clinical trials may not be indicative of the results of later-stage or larger-scale clinical trials.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.